KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings: 2018-2024

Historic Retained Earnings for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to -$1.6 billion.

  • Esperion Therapeutics' Retained Earnings fell 6.70% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 6.70%. This contributed to the annual value of -$1.6 billion for FY2024, which is 3.34% down from last year.
  • Esperion Therapeutics' Retained Earnings amounted to -$1.6 billion in FY2024, which was down 3.34% from -$1.5 billion recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Retained Earnings registered a high of -$838.8 million during FY2020, and its lowest value of -$1.6 billion during FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$1.5 billion (2023), whereas its average is -$1.5 billion.
  • Data for Esperion Therapeutics' Retained Earnings shows a maximum YoY tumbled of 31.90% (in 2021) over the last 5 years.
  • Esperion Therapeutics' Retained Earnings (Yearly) stood at -$838.8 million in 2020, then tumbled by 31.90% to -$1.1 billion in 2021, then decreased by 21.12% to -$1.3 billion in 2022, then fell by 15.62% to -$1.5 billion in 2023, then declined by 3.34% to -$1.6 billion in 2024.